🇺🇸 FDA
Pipeline program

VEGF Trap-Eye (BAY86-5321)

91745

Phase 3 mab completed

Quick answer

VEGF Trap-Eye (BAY86-5321) for Diabetes Mellitus is a Phase 3 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Diabetes Mellitus
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials